Gilead­'s selon­sert­ib fails PhI­II in less sick NASH pa­tients — to no one's sur­prise

The prospects of Gilead’s top late-stage NASH drug selon­sert­ib grew dim when it kicked off Phase III read­outs with a flop. Two months lat­er, the com­pa­ny con­ced­ed that a sec­ond, much sim­i­lar tri­al has al­so failed.

STEL­LAR-3 set out to mea­sure how well selon­sert­ib, an oral in­hibitor of apop­to­sis sig­nal-reg­u­lat­ing ki­nase 1 (ASK1), can im­prove fi­bro­sis with­out NASH wors­en­ing. That’s the same pri­ma­ry end­point as STEL­LAR-4, ex­cept that STEL­LAR-3 re­cruit­ed pa­tients at a slight­ly ear­li­er stage of dis­ease — with F3, or bridg­ing, fi­bro­sis — com­pared to the cir­rho­sis (F4 fi­bro­sis) pa­tients en­rolled in the oth­er tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.